OncoTherapy Science, Inc.
4564.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | -0.03 | 0.45 | 0.32 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -27.65 | -23.69 | -59.16 | -34.65 |
| Quality | ||||
| ROIC | -10.02% | -26.08% | -14.24% | -17.75% |
| Gross Margin | 14.15% | -1.75% | 5.93% | 11.96% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -0.69% | -1.74% | -12.91% | -22.48% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 6.89 | 3.80 | 6.79 | 5.16 |
| Interest Coverage | -524.43 | -929.43 | -360.23 | -509.15 |
| Efficiency | ||||
| Inventory Turnover | 2.15 | 1.83 | 2.23 | 4.27 |
| Cash Conversion Cycle | 59.34 | 73.57 | 88.04 | 45.83 |